Fulcrum Therapeutics Announces Stock Options Grant
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company dedicated to developing small molecules that aim to improve the lives of patients with genetically defined rare diseases, has announced a new stock option grant. This move aligns with Nasdaq Listing Rule 5635(c)(4) and follows the company's amended 2022 Inducement Stock Incentive Plan.
Details on Stock Options Granted
As part of their onboarding process, the company has granted non-statutory stock options to two new employees. One employee received options to purchase 350,000 shares of the company’s common stock at an exercise price of $9.34 per share, reflecting the closing price on the effective date of the grant. The other new employee was granted 270,000 options at an exercise price of $8.43 per share. Each stock option comes with a ten-year term and vests over four years—25% will vest on the first anniversary of the employee’s start date, with an additional 6.25% vesting in equal quarterly installments over the next twelve quarters, contingent upon the employee's continued service.
About Fulcrum Therapeutics
Fulcrum Therapeutics is dedicated to the clinical development of innovative small molecules that address significant unmet medical needs in rare diseases. Their lead clinical programs include losmapimod, which targets facioscapulohumeral muscular dystrophy (FSHD), and pociredir, which aims to increase fetal hemoglobin levels for treating sickle cell disease (SCD). The company utilizes proprietary technology to identify and target drug mechanisms that can modulate gene expression, effectively addressing the root causes of gene mis-expression.
The Commitment to Rare Diseases
Fulcrum’s focused approach to rare diseases underscores its significant role in the biopharmaceutical sector. By concentrating on conditions that currently lack effective treatment options, Fulcrum Therapeutics is making a vital contribution to the industry, striving to provide solutions for patients who have limited therapeutic alternatives.
Company Contact Information
For any inquiries, please reach out to Chris Calabrese from LifeSci Advisors, LLC at ccalabrese@lifesciadvisors.com or by phone at 917-680-5608.
Frequently Asked Questions
What is the latest announcement by Fulcrum Therapeutics?
Fulcrum Therapeutics announced the granting of stock options to two new employees as part of their strategy linked to the Nasdaq Listing Rule 5635(c)(4).
How many stock options were granted?
One new employee received 350,000 options, while another was granted 270,000 options to purchase shares of the company’s common stock.
What is the exercise price of the granted stock options?
The exercise prices are set at $9.34 and $8.43 per share, corresponding to the closing prices on the respective grant effective dates.
What is the focus of Fulcrum Therapeutics?
Fulcrum Therapeutics is focused on developing therapeutics for genetically defined rare diseases, especially targeting those with high unmet medical needs.
Who can be contacted for more information about Fulcrum Therapeutics?
Inquiries can be directed to Chris Calabrese from LifeSci Advisors, LLC at ccalabrese@lifesciadvisors.com or via phone at 917-680-5608.
